Name
OÜ PharmaFour
Registry code
14518678
VAT number
EE102129067
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
03.07.2018 (6)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
47731 - Dispensing chemist in specialised stores
3 364 198 €
32 328 €
1%
2 522 €
(estimate is approximate)
-129 177 €
3
Submitted
No tax arrears
-25%
2%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Omanikukonto: LJUBOV VOLOŠTŠUK 05.10.1987 (37) | 100% - 2 500.00 EUR | Board member | Direct ownership |
| 2019 06.11.2020 | 2020 30.06.2021 | 2021 17.06.2022 | 2022 14.06.2023 | 2023 18.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 722 365 € | 2 767 163 € | 3 262 115 € | 3 226 907 € | 3 364 198 € |
| Net profit (loss) for the period | -110 492 € | -224 207 € | 165 465 € | 5 230 € | 32 328 € |
| Profit Margin | -15% | -8% | 5% | 0% | 1% |
| Current Assets | 235 008 € | 792 067 € | 714 121 € | 859 845 € | 869 454 € |
| Fixed Assets | 131 252 € | 758 194 € | 681 495 € | 604 040 € | 646 557 € |
| Total Assets | 366 260 € | 1 550 261 € | 1 395 616 € | 1 463 885 € | 1 516 011 € |
| Current Liabilities | 474 252 € | 1 882 460 € | 1 562 350 € | 1 625 390 € | 1 645 188 € |
| Non Current Liabilities | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Share Capital | - | - | - | - | - |
| Equity | -107 992 € | -332 199 € | -166 734 € | -161 505 € | -129 177 € |
| Employees | 5 | 7 | 1 | 2 | 3 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 940 639.76 € | 7 275.83 € | 12 166.69 € | 3 |
| 2023 Q4 | 948 610.28 € | 9 745.35 € | 12 429.87 € | 3 |
| 2023 Q3 | 743 374.12 € | 8 682.06 € | 12 831.97 € | 3 |
| 2023 Q2 | 787 421.18 € | 8 282.39 € | 12 048.22 € | 3 |
| 2023 Q1 | 811 673.95 € | 8 384.98 € | 11 868.2 € | 3 |
| 2022 Q4 | 923 382.06 € | 5 635.05 € | 11 822.92 € | 3 |
| 2022 Q3 | 695 200.84 € | 9 135.9 € | 12 623.74 € | 3 |
| 2022 Q2 | 784 467.7 € | 4 892.58 € | 6 236.22 € | 3 |
| 2022 Q1 | 809 737.41 € | 304.47 € | 4 855.86 € | 1 |
| 2021 Q4 | 951 543.21 € | 12 621 € | 5 918.72 € | 1 |
| 2021 Q3 | 742 090.16 € | 8 724.46 € | 5 740.15 € | 1 |
| 2021 Q2 | 807 830.3 € | 8 158.08 € | 6 341.21 € | 1 |
| 2021 Q1 | 829 214.1 € | 7 509.69 € | 4 888.35 € | 1 |
| 2020 Q4 | 990 373.97 € | 11 755.05 € | 11 960.76 € | 1 |
| 2020 Q3 | 756 714.77 € | 17 226.35 € | 18 720.71 € | 7 |
| 2020 Q2 | 631 121.96 € | 13 436.99 € | 14 573.9 € | 7 |
| 2020 Q1 | 277 229.95 € | 12 788.75 € | 13 865.74 € | 8 |
